Cargando…

Effect of rAd5-Vector HIV-1 Preventive Vaccines on HIV-1 Acquisition: A Participant-Level Meta-Analysis of Randomized Trials

BACKGROUND: Three phase 2b, double-blind, placebo-controlled, randomized efficacy trials have tested recombinant Adenovirus serotype-5 (rAd5)-vector preventive HIV-1 vaccines: MRKAd5 HIV-1 gag/pol/nef in Step and Phambili, and DNA/rAd5 HIV-1 env/gag/pol in HVTN505. Due to efficacy futility observed...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huang, Yunda, Follmann, Dean, Nason, Martha, Zhang, Lily, Huang, Ying, Mehrotra, Devan V., Moodie, Zoe, Metch, Barbara, Janes, Holly, Keefer, Michael C., Churchyard, Gavin, Robb, Merlin L., Fast, Patricia E., Duerr, Ann, McElrath, M. Juliana, Corey, Lawrence, Mascola, John R., Graham, Barney S., Sobieszczyk, Magdalena E., Kublin, James G., Robertson, Michael, Hammer, Scott M., Gray, Glenda E., Buchbinder, Susan P., Gilbert, Peter B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4558095/ https://www.ncbi.nlm.nih.gov/pubmed/26332672 http://dx.doi.org/10.1371/journal.pone.0136626

Ejemplares similares

Immune-Correlates Analysis of an HIV-1 Vaccine Efficacy Trial Reveals an Association of Nonspecific Interferon-γ Secretion with Increased HIV-1 Infection Risk: A Cohort-Based Modeling Study
por: Huang, Yunda, et al.
Publicado: (2014)

Benign ethnic neutropenia in a South African population, and its association with HIV acquisition and adverse event reporting in an HIV vaccine clinical trial
por: Mpofu, Rephaim, et al.
Publicado: (2021)

DNA plasmid HIV vaccine design, number of doses, participant gender, and body mass index affect T-cell responses across HIV vaccine clinical trials
por: Morgan, C, et al.
Publicado: (2012)

P14-02. Social impact events in Phambili, the first phase 2B HIV vaccine trial in South Africa
por: Allen, MA, et al.
Publicado: (2009)

Impact of vaccine type on HIV-1 vaccine elicited antibody durability and B cell gene signature
por: Palli, Rohith, et al.
Publicado: (2020)

Pre-Existing Adenovirus Immunity Modifies a Complex Mixed Th1 and Th2 Cytokine Response to an Ad5/HIV-1 Vaccine Candidate in Humans
por: Pine, Samuel O., et al.
Publicado: (2011)

Continued Follow-Up of Phambili Phase 2b Randomized HIV-1 Vaccine Trial Participants Supports Increased HIV-1 Acquisition among Vaccinated Men
por: Moodie, Zoe, et al.
Publicado: (2015)

P15-08. Did unblinding affect HIV risk behaviour and risk perception in the HVTN503/Phambili study?
por: Gray, GE, et al.
Publicado: (2009)

Immunization with Cocktail of HIV-Derived Peptides in Montanide ISA-51 Is Immunogenic, but Causes Sterile Abscesses and Unacceptable Reactogenicity
por: Graham, Barney S., et al.
Publicado: (2010)

COVID-19 vaccination and HIV-1 acquisition – Authors’ reply
por: Buchbinder, Susan P, et al.
Publicado: (2022)

Baseline host determinants of robust human HIV-1 vaccine-induced immune responses: A meta-analysis of 26 vaccine regimens
por: Huang, Yunda, et al.
Publicado: (2022)

Sequence and vector shapes vaccine induced antibody effector functions in HIV vaccine trials
por: Fischinger, Stephanie, et al.
Publicado: (2021)

P14-07. Offering new prevention modalities in HIV vaccine trials: experience with male circumcision in the Phambili trial
por: de Bruyn, G, et al.
Publicado: (2009)

Meta-analysis of HIV-1 vaccine elicited mucosal antibodies in humans
por: Seaton, Kelly E., et al.
Publicado: (2021)

A Phase IIA Randomized Clinical Trial of a Multiclade HIV-1 DNA Prime Followed by a Multiclade rAd5 HIV-1 Vaccine Boost in Healthy Adults (HVTN204)
por: Churchyard, Gavin J., et al.
Publicado: (2011)

HIV vaccine trial safety and retention among 18-20 year olds in the HVTN 503/Phambili study support the inclusion of adolescents in future trials
por: Volk, JE, et al.
Publicado: (2012)

Effect of HIV Envelope Vaccination on the Subsequent Antibody Response to HIV Infection
por: Ditse, Zanele, et al.
Publicado: (2020)

The aspirational necessity of HIV prevention
por: Corey, Lawrence, et al.
Publicado: (2019)

HIV-1 Vaccine-Induced T-Cell Reponses Cluster in Epitope Hotspots that Differ from Those Induced in Natural Infection with HIV-1
por: Hertz, Tomer, et al.
Publicado: (2013)

Innate immune signatures to a partially-efficacious HIV vaccine predict correlates of HIV-1 infection risk
por: Andersen-Nissen, Erica, et al.
Publicado: (2021)

Risk Factors Associated with HIV Acquisition in Males Participating in HIV Vaccine Efficacy Trials in South Africa
por: Malahleha, Mookho, et al.
Publicado: (2023)

Safety and Immunogenicity of a Replication-Defective Adenovirus Type 5 HIV Vaccine in Ad5-Seronegative Persons: A Randomized Clinical Trial (HVTN 054)
por: Peiperl, Laurence, et al.
Publicado: (2010)

Immunogenicity of a novel Clade B HIV-1 vaccine combination: Results of phase 1 randomized placebo controlled trial of an HIV-1 GM-CSF-expressing DNA prime with a modified vaccinia Ankara vaccine boost in healthy HIV-1 uninfected adults
por: Buchbinder, Susan P., et al.
Publicado: (2017)

HIV-1 infections with multiple founders are associated with higher viral loads than infections with single founders
por: Janes, Holly, et al.
Publicado: (2015)

Mycobacterium tuberculosis infection, immune activation, and risk of HIV acquisition
por: Bender Ignacio, Rachel A., et al.
Publicado: (2022)

0A07-01. HIV-specific CD8(+ )T-cells of vaccinees exhibit proliferative and cytotoxic capacities comparable to those of progressors
por: Rood, JE, et al.
Publicado: (2009)

Cross-protocol assessment of induction and durability of VISP/R in HIV preventive vaccine trial participants
por: Espy, Nicole, et al.
Publicado: (2023)

Landscapes of binding antibody and T-cell responses to pox-protein HIV vaccines in Thais and South Africans
por: Zhao, Lue Ping, et al.
Publicado: (2020)

Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: Results of a phase 1 randomized trial
por: Mayer, Kenneth H., et al.
Publicado: (2017)

Decreased Pre-existing Ad5 Capsid and Ad35 Neutralizing Antibodies Increase HIV-1 Infection Risk in the Step Trial Independent of Vaccination
por: Cheng, Cheng, et al.
Publicado: (2012)

Correction: Decreased Pre-existing Ad5 Capsid and Ad35 Neutralizing Antibodies Increase HIV-1 Infection Risk in the Step Trial Independent of Vaccination
por: Cheng, Cheng, et al.
Publicado: (2012)

Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial
por: Bekker, Linda-Gail, et al.
Publicado: (2018)

Predictors of HVTN 503 MRK-AD5 HIV-1 gag/pol/nef Vaccine Induced Immune Responses
por: Hopkins, Kathryn L., et al.
Publicado: (2014)

P17-25. A model for coverage of T-cell HIV vaccines: where are we and where do we need to be?
por: Self, S, et al.
Publicado: (2009)

Assessing Durability of Vaccine Effect Following Blinded Crossover in COVID-19 Vaccine Efficacy Trials
por: Follmann, Dean, et al.
Publicado: (2020)

Mathematical modeling to reveal breakthrough mechanisms in the HIV Antibody Mediated Prevention (AMP) trials
por: Reeves, Daniel B., et al.
Publicado: (2020)

Safety and immunogenicity of a multivalent HIV vaccine comprising envelope protein with either DNA or NYVAC vectors (HVTN 096): a phase 1b, double-blind, placebo-controlled trial
por: Pantaleo, Giuseppe, et al.
Publicado: (2019)

HIV-1 Induces Cytotoxic T Lymphocytes in the Cervix of Infected Women
por: Musey, Luwy, et al.
Publicado: (1997)

DNA priming and gp120 boosting induces HIV-specific antibodies in a randomized clinical trial
por: Rouphael, Nadine G., et al.
Publicado: (2019)

Pregnancy Incidence and Correlates during the HVTN 503 Phambili HIV Vaccine Trial Conducted among South African Women
por: Latka, Mary H., et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_j2264kj82lp3nbo3lbcefhkpct